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Abstract: Glaesserella (Haemophilus) parasuis, an early colonizer of the nasal cavity in piglets, is a
highly heterogeneous species, comprising both commensal and virulent strains. Virulent G. parasuis
strains can cause fibrinous polyserositis called Glässer’s disease. Colostrum is a source of passive
immunity for young piglets. When vaccinating sows, protective antibodies are transferred to their
offspring through the colostrum. Here, sow vaccination was performed with a protein fragment, F4,
from the outer membrane trimeric autotransporters VtaAs exclusively found in virulent G. parasuis.
Piglets were allowed to suckle for 3 weeks, following which a challenge with two virulent strains
of G. parasuis was performed. A group of nonvaccinated sows and their piglets were included as a
control. Antibodies against F4 were confirmed using ELISA in the vaccinated sows and their offspring
before the G. parasuis challenge. Compared to the control group, F4-vaccination also resulted in an
increased level of serum TGF-β both in vaccinated sows and in their offspring at early time points of
life. After the challenge, a lower body temperature and a higher weight were observed in the group of
piglets from vaccinated sows. One piglet from the non-vaccinated group succumbed to the infection,
but no other significant differences in clinical signs were noticed. At necropsy, performed 2 weeks
after the virulent challenge, the level of surfactant protein D (SP-D) in bronchoalveolar lavage was
higher in the piglets from vaccinated sows. Vaccination did not inhibit the nasal colonization of the
piglets by the challenge strains.
Keywords: swine; bacteria; disease; vaccine; Glaesserella parasuis
1. Introduction
Glaesserella parasuis, formerly known as Haemophilus parasuis, is a rod shaped, Gram-
negative proteobacteria from the Pasteurellaceae family that is commonly found in the nasal
microbiota of pigs. G. parasuis is a highly heterogeneous species, comprising commensal
and virulent strains. Virulent strains can cause polyserositis, polyarthritis and meningitis,
a pathological disorder called Glässer’s disease that is more prevalent in young piglets,
especially in the nursery period.
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The most commonly used treatment for Glässer’s disease and other bacterial diseases
affecting piglets are antimicrobials. However, increasing concern about antimicrobial
resistance arising from the livestock industry is promoting the research of alternative
control tools, where vaccines have a relevant role [1].
G. parasuis is an extracellular pathogen, and the induction of opsonizing antibodies
(for example, by vaccination) is essential for protection against disease [2,3]. Prevention
of Glässer’s disease may be achieved with attenuated bacteria, inactivated bacterins and
subunit vaccines [4]. However, commercial bacterins do not provide protection against
all G. parasuis strains, promoting the search for alternative vaccines that could confer
cross-protection among virulent strains of different serovars. Several vaccine candidates
have been proposed in the literature [4], including virulence factors such as the virulence-
associated trimeric autotransporters (VtaA), which are involved in phagocytosis resis-
tance [5] and adhesion to extracellular matrix proteins [6]. In a previous study from our
group, immunization with a combination of six VtaA proteins provided partial protection
against a lethal infection with a virulent G. parasuis strain in colostrum deprived piglets [7].
A detailed study of the sequences of these proteins identified a peptide (F4) that was
present in the VtaAs associated with virulent strains and was exposed on the bacterial
surface [8], supporting its potential as a vaccine candidate.
In swine, maternal immunity is transferred to the litter via colostrum and progressively
decreases with the age of the piglets, while the maturation of the immune system of the
piglet is not yet complete [8,9]. Sow vaccination increases the level of colostrum antibodies
and, subsequently, the period when maternal antibodies are maintained at a detectable
level in their offspring [10,11]. For this reason, together with the short window available
for piglet vaccination and their immature immune system, maternal immunization can be
an option to prevent diseases early in life [12–15].
Here, we evaluate the effect on the offspring of sow vaccination using adjuvanted F4
peptide as an immunogen and the protection observed in the piglets after an intranasal
challenge with two different virulent strains of G. parasuis.
2. Materials and Methods
2.1. Vaccine and Challenge Strains
The protein fragment F4, consisting of amino acids 701 to 874 from the trimeric
autotransporter VtaA9 from G. parasuis [8], was used as an immunogen in combination
with a carbomer-based adjuvant. Vaccine formulation was composed of the purified F4
fragment mixed with Carbopol 5984 EP Polymer (1:9) (Lubrizol, Cleveland, OH, USA) to
achieve a final concentration of 100 µg/mL of F4 peptide (#F4 API VACSUIS, WorldPathol,
Zaragoza, Spain).
G. parasuis strains Nagasaki (virulent reference strain serovar 5 [SV5]) and P555/04
(clinical isolate from pericardium, serovar 13 [SV13], provided by Dr. Zielinski from INTA-
Argentina), were grown overnight on chocolate agar plates (Biomérieux, Marcy-L’Étoile,
France) at 37 ◦C 5% CO2 and were used for the intranasal inoculation of piglets.
2.2. Animal Study
Animal experimentation was performed in the BSL3 facilities of IRTA-CReSA (Bel-
laterra, Spain) following proper veterinary practices, in accordance with European (Directive
2010/63/EU) and Spanish (Real Decreto 53/2013) regulation and with the approval of the
Ethics Commission in Animal Experimentation of the Generalitat de Catalunya (Protocol
number 9211). The experimental procedure is represented in Figure 1. Four pregnant sows
were selected on the basis of low antibody levels against G. parasuis using the commercial
ELISA Ingezim–Haemophilus (Ingenasa, Madrid, Spain). Two sows were vaccinated at 32
and 12 days before farrowing with 2.5 mL of the F4 vaccine, while the other two sows re-
mained unvaccinated as controls. Serum samples were taken from the sows at each time of
vaccination and at delivery. In addition, colostrum samples were taken at delivery. After
birth, piglets suckled from their mother for 1 day and then the litters were cross-fostered
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within each experimental group. One vaccinated sow (with five of its own piglets and six
from the other vaccinated sow) and one nonvaccinated control sow (with nine of its own
piglets and eight from the other control sow) remained in the study. Sows were removed
from the study at day 18 (D18). At 1, 2 and 3 weeks of age, nasal samples were taken from the
piglets for G. parasuis detection. At 1, 2 and 3 weeks, serum samples were also obtained. One
day later (D22), piglets were divided into two groups for the challenge, with piglets from the
different biological sows in each group. Thus, nine piglets from nonvaccinated sows and six
from vaccinated sows were intranasally inoculated using an atomizer with 6 × 109 colony
forming units (CFU) of Nagasaki (SV5) with a total inoculation volume of 1.5 mL per piglet,
while eight piglets from nonvaccinated sows and five from vaccinated sows were intranasally
inoculated with 3 × 109 CFU of P555/04 (SV13) in 1.5 mL (Figure 1). After 16 (P555/04 group)
and 17 (Nagasaki group) days of challenge, final sampling and necropsies were performed for
pathological examination and samples from different tissues were taken for analysis. Serum
and bronchoalveolar lavage fluid (BALF) were also taken for immunological analysis.
Figure 1. Schematic representation of the animal experiment. Two sows (in pale and dark blue) were
vaccinated with VtaA fragment F4 at days −32 and −12 of farrowing, while two sows served as
unvaccinated controls (in pale and dark pink). Al birth, D0, piglets (color indicates the sow of origin)
were cross-fostered within each group and only one sow per group stayed in the study. Later, piglets
were split in groups for inoculation at day 22 with two different serovars of G. parasuis: Nagasaki
strain (SV5) represented in the upper part of the graph; and P555/04 (SV13) in the lower part. After
2 weeks, necropsies and final sampling were performed. Sampling points during the experiment
were days 7, 15 and 21.
2.3. Clinical Signs and Pathological Assessment
Rectal temperatures, weight and clinical signs (particularly those compatible with
Glässer’s disease) were evaluated after the challenge with G. parasuis. Fever was considered
to be a rectal temperature above 40 ◦C. Clinical signs were scored daily for each piglet, and
later, a global clinical score was used for analysis: 0 = no symptoms; 1 = clinical signs on
1 day; 2 = clinical signs on more than 1 day; 3 = severe clinical signs (euthanasia).
Gross lesions were assessed in necropsy and the presence of G. parasuis in different
organs was determined by culturing samples from body cavities (pericardic, thoracic and
abdominal), four joints and blood.
Samples from the lung, trachea and nasal turbinate were taken for histopathological
examination. Formalin fixed tissues were embedded in paraffin and 3–5 µm sections were
cut for haematoxylin-eosin staining. Assessment of lymphoplasmacytic inflammation was
scored as: 0, absence; 1, mild; 2, moderate; 3, severe.
2.4. DNA Extraction and G. parasuis Detection by PCR
Nasal swabs were resuspended in 500 µL of PBS and 200 µL of the suspensions were
processed using the Nucleospin Blood kit (Macherey-Nagel, Düren, Germany) according
to the manufacturer’s instructions. For pure bacterial cultures, DNA was extracted using
a Chelex based Instagene Matrix (Bio-Rad Laboratories, Hercules, CA, USA) following
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the manufacturer’s instructions. G. parasuis was detected and differentiated into virulent
and nonvirulent using a specific vtaA leader sequence PCR (LS-PCR) [16]. In some cases,
additional molecular serotyping PCR was performed for serovars 5/12 and 13 [17]. Four
µL of the DNA extracted from the nasal swabs or two µL of the purified DNA from pure
cultures were used as template for the reactions. DNA from strains Nagasaki (serovar 5,
virulent), P555/04 (serovar 13, virulent) and SW114 (nonvirulent) were included as controls
for the PCRs. Primers used in the PCRs can be found in Table S1.
2.5. Antibody Response
Antibodies were measured using ELISA as follows: High binding plates were coated
overnight at 4 ◦C with F4 protein (500 ng/well) in a carbonate–bicarbonate buffer. After
washing, wells were blocked with 1% casein in phosphate-buffered saline (PBS) with 0.05%
Tween 20 (PBS-Tw). Sera and colostrum were diluted 1:1000 in blocking solution and BALF
samples were used undiluted. After an incubation of 1h at 37 ◦C, a goat antiporcine IgG
HRP-conjugated antibody (Sigma-Aldrich, Madrid, Spain) was used for IgG detection at
a 1:10,000 dilution in blocking solution. For IgA detection in BALF, samples were tested
undiluted and detected with an HRP-conjugated goat anti-porcine IgA antibody (AbD
Serotec, Oxford, UK) diluted 1:10,000. Finally, positive reactions were developed using
the 3,3,3,5-tetramethylbenzidine (TMB) substrate (Sigma-Aldrich, Madrid, Spain) and the
reaction was stopped with 1N sulfuric acid. Plates were then read in a Power Wave XS
spectrophotometer (Biotech, Winooski, VT, USA) at 450 nm.
2.6. Interleukin Determination
Serum levels of IL-8, IL-10, TNF-α and TGF-β were evaluated via ELISA using dif-
ferent products. Two matched antibody pairs for swine IL-10 and TNF-α from Kingfisher
Biotech (Saint Paul, MN, USA) and an ELISA kit from the same manufacturer for porcine
IL-8 were used. TGF-β was evaluated using a TGF-β Human Matched Antibody Pair
kit from Invitrogen (Carlsbad, CA, USA), following the manufacturer’s instructions in
all cases.
2.7. Surfactant Protein D (SP-D) Monoclonal Antibodies Production and SP-D Determination
by ELISA
Surfactant protein D (SP-D) was determined via an in-house sandwich ELISA using a
monoclonal antibody pair (capture and detection) from hybridoma supernatants, whose
production was performed as follows. Briefly, lung SP-D was extracted and purified from
the BALF of healthy piglets following previously described protocol [18]. Hybridomas
were generated by immunizing BALB/c mice with the purified SP-D using standard
procedures described before [19] and with the approval of the Ethics Commission in
Animal Experimentation from the Generalitat de Catalunya (Approved protocol 5767).
Two monoclonal antibodies were selected according to their strong signal against the
SP-D antigen via indirect ELISA, and their isotype was determined using a mouse typer
isotyping kit (Bio-Rad, Hercules, CA, USA), following the manufacturer’s indications.
Selected clones were R-133 (IgG2b) (used as a capture antibody) and R-123 (IgG1) (used
for detection).
For ELISA, high binding 96 well plates were coated with 50 µL of the capture antibody
hybridoma supernatant R-133 diluted 1:1 in carbonate bicarbonate buffer overnight at
4 ◦C. After coating, plates were washed and blocked with blocking solution as above
for 1 h at 37 ◦C. After an incubation of 50 µL of undiluted BALF for 1h at 37 ◦C, the
plates were washed, and a detection antibody mixture, which consisted of a mixture 1:1
of the hybridoma supernatant R-123 with blocking buffer, was added to the wells. After
incubation for 1 h at 37 ◦C and washes, ELISA plates were finally incubated for 1 h at 37 ◦C
with an HRP-conjugated goat anti-mouse IgG1 antibody (Invitrogen, Carlsbad, CA, USA)
diluted 1:1000. Finally, reaction was developed with TMB for 5–10 min, and stopped with
1N sulfuric acid before reading at 450 nm.
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2.8. Statistical Analysis and Modelling
At first, the collected data were screened for unlikely or missing values before run-
ning any valid statistical analysis. No data were excluded on this basis. Subsequently, a
descriptive statistical analysis was performed to the potential predictors related to piglets
and sows in the experiment with the main variables of interest: clinical signs, biological
sows, sow vaccination, challenge strain and colonization with virulent strains of G. parasuis
(GP.VIR) or nonvirulent strains (GP.NVIR) at the end of the study.
Different statistical models of multilevel multivariable linear regression with repeated
measurements were run for the following continuous outcome variables: IL-8, IL-10, TGF-β,
antibody levels against F4, SP-D levels in BALF, rectal temperature, weight after challenge,
IgG against F4 in BALF, total IgG in BALF and ratio of α-F4 IgG/total IgG. Sow-ID was
accounted as a random effect in the different models. The outcome variable that showed
skew pattern was, therefore, transformed by taking their natural logarithm or log10.
A univariable model analysis was carried out to test the unconditional associations
between dependents and different independent variables of interest. Only independent
variables with p ≤ 0.25 in this initial screening were included in multivariable linear
regression models [20]. Before proceeding with building our multivariable model analysis,
we checked for correlations between the retained independent variables. If two variables
were highly correlated (R > 0.8), only the one with the lower p value in the unconditional
associations was retained.
The significant predictors from the univariable analysis were then offered to a mul-
tivariable model, and a manual backward elimination procedure was used to the least
significant variable (p > 0.05) if their exclusion from the model did not result in a greater
than 30% change (confounding effect) in the effects of the remaining variables in the
model [20].
The generated final model included only variables with a p value ≤ 0.05. In this model,
two-way interactions between the remaining significant variables were investigated and
were retained if significant. The p value and regression coefficient (b) with a 95% confidence
interval (95% CI) were recorded for each variable. In all statistical analyses, the results
were considered to be significant with a p ≤ 0.05.
All statistical analyses were conducted using R version 3.3.3 (R Core Team, 2015).
3. Results
3.1. Sow Vaccination with F4 Induces Specific Antibodies and TGF-β in the Offspring
The response to vaccination in sows was evaluated in colostrum and serum at different
times postvaccination (Figure 2A). It is noteworthy that one of the vaccinated sows showed
higher level of antibodies against F4 than did the other sow. As expected, sera from
piglets reflected the vaccination of the sows, with higher level of antibodies against F4 in
piglets nursed by vaccinated sows than in piglets from unvaccinated sows. Antibody levels
showed a decreasing tendency during the first two weeks of life and a stabilizing tendency
between the second and the third week of life, at the time of the G. parasuis challenges
(Figure 2B). Interestingly, the level of F4 antibodies dramatically decreased immediately
after the G. parasuis challenges until the end of the experiment (Figure 2B), most probably
reflecting the specific sequestering of F4-specifcic antibodies by the bacteria. As expected,
the multivariable statistical model showed a significative association of the level of F4
antibodies (Log10 of ELISA absorbance) with sow vaccination (p = 1.53 × 10−11; Table 1).
Vaccinated sows had higher TGF-β levels in serum and colostrum at the time of
farrowing (Figure 3A), with each one responding differently. In piglets, TGF-β levels in
sera were higher in animals from vaccinated sows than in those from nonvaccinated ones at
7 and 15 days of life (two-tailed Student t test, p < 0.0001 for both days), but values stabilized
and were similar in both groups of piglets just before the challenge at D21 (Figure 3B).
In addition, a correlation between the level of F4-antibodies and TGF-β in the piglets at
7 days of life was observed (R = 0.68). To study the association between TGF-β levels and
other parameters, values were log-transformed to achieve normal distribution. Statistical
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multivariable model confirmed the significant association of sow vaccination with TGF-β
levels in piglets (p = 1.281 × 10−5). Piglets from vaccinated sows had a higher log level of
TGF-β by 0.498 (95% CI 0.241–0.757) in comparison to piglets from nonvaccinated sows.
Figure 2. Levels of IgG against F4 in samples from sows (A) and their piglets (B). (A), Two sows
were vaccinated (black symbols) with F4 at 4 (day −32) and 2 (day −12) weeks before farrowing.
Two sows remained unvaccinated as control (white symbols). Serum samples at vaccination times,
farrowing (D0) and at weaning (3 weeks after farrowing) (as well as colostrum samples) were tested
for F4 antibodies using ELISA. (B), Serum samples from piglets nursed by vaccinated (black circles)
or nonvaccinated (white circles) sows taken at 1, 2, 3 and 5 weeks of life were tested for F4 antibodies
by ELISA. At 22 days of life, piglets were challenged with G. parasuis. The average absorbance in the
ELISA is shown in the graph. Error bars represent the standard deviation. Individual piglet results
can be found in Figure S1.
Table 1. Final model with the association of the log10 transformed ELISA values against F4 and
predictor variables using generalized additive model.





Clinical signs Absence Ref Ref 0.0083
Presence 0.105 0.029–0.181
Although the levels of IL-8 in sera were low through the study, log IL-8 levels in the
piglets were also associated with sow vaccination (Figure 4A and Table 2), and, in addition,
it was negatively correlated with the colonization of the piglets with G. parasuis virulent
strains at the end of the study (Table 2). The opposite tendency was observed with IL-10
and vaccination (Figure 4B), since piglets from vaccinated sows had lower log IL-10 levels
by −0.093 in comparison to piglets from nonvaccinated sows. Again, the levels of IL-10
through the study were kept low. TNF-α in serum displayed values below the detection
limit of the technique in all the samples.
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Figure 3. Levels of TGF-β in samples from sows (A) and their piglets (B). The concentration of TGF-β
in serum samples taken in sows and piglets at vaccination times, farrowing and weaning (3 weeks
after farrowing) (as well as in colostrum sample), was measured using ELISA. (A), Two sows (black
symbols) were vaccinated with F4 at 4 (day-32) and 2 (day-12) weeks before farrowing. The other two
sows remained unvaccinated as control (white symbols). (B), Serum samples from piglets nursed by
vaccinated (black circles) or nonvaccinated (white circles) sows were taken at 1, 2, 3 and 5 weeks of
life. At 22 days of life, piglets were challenged with G. parasuis. The average concentration of serum
TGF-β in each group is shown in the graph. Error bars are the standard deviation. Individual piglet
results can be found in Figure S2.
Figure 4. Levels of IL-8 (A) and Il-10 (B) in sera from piglets born to vaccinated and nonvaccinated
sows. Serum samples were taken at 7, 15 and 21 days of life. Empty dots represent the piglets from
nonvaccinated sows, whereas black dots represent piglets nursed by vaccinated ones. Individual
piglet results can be found in Figure S3A,B.
Table 2. Final model with the association of log10 IL-8 and predictor variables using multivariable
mixed linear regression with time as a random effect. GP.VIR: colonization of the nasal cavity of the
piglets with virulent G. parasuis strains at the end of the study.
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3.2. Clinical Signs and Pathological Findings after Virulent G. parasuis Challenge
Piglets were weaned and then distributed into two groups and challenged at D22 with
two different virulent G. parasuis strains (Figure 1). Rectal temperatures were taken after the
infection with the virulent G. parasuis. The final multivariable model showed a significant
association between the body temperature of the piglets and sow vaccination. We found
that piglets nursed by vaccinated sows had lower rectal temperature after challenge by
−0.095 in comparison to the piglets of nonvaccinated sows (Table 3).
Table 3. Final model with the association of body temperature of piglets and other predictor variables
using multivariable linear regression with repeat measurements while accounting for sow identity as
random effect.









Clinical signs Absence Ref Ref 0.0702
Presence −0.045 (−0.092)–0.003
After challenge, only one piglet infected with the Nagasaki strain from the unvac-
cinated sow group succumbed to the infection and showed severe lesions of Glässer’s
disease, presenting fibrin aggregates in the pericardium, thoracic and abdominal cavities.
The rest of the piglets showed mild clinical signs. Regarding the strain used in the challenge,
more animals infected with Nagasaki presented clinical signs (9/15) than those infected
with P555/04 (5/13), but no significant differences between piglets from vaccinated or
nonvaccinated sows were detected within the two challenge groups in terms of disease
outcome. Unexpectedly, the antibody levels against F4 were significantly associated in
piglets with clinical signs (p = 0.0083; Table 1). However, a close examination of the groups
showed that the group challenged with Nagasaki (which caused more clinical signs due to
its higher virulence) also contained more piglets with higher level of antibodies before the
challenge. This may at least in part explain this unexpected observation.
Microscopical observation of hematoxylin/eosin-stained nasal turbinates showed that
animals infected with the Nagasaki strain presented a higher inflammation score than
animals infected with P555/04 (Fisher’s exact test, p = 0.006). However, no significant
differences were found between piglets from vaccinated or nonvaccinated sows.
3.3. Weight Gain after Challenge
The weight of the animals was monitored after challenge, and piglets from vaccinated
sows gained significantly more average weight (by 1.159 units) than piglets from unvacci-
nated ones (Table 4). Our findings also showed that the colonization of the nasal mucosa
of piglets with nonvirulent G. parasuis at the time of necropsies (GP.NVIR on Table 4) was
associated with an increase in their average weight by 1.148 units in comparison to piglets
without this colonization.
Table 4. Final model with the association of body weight of piglets after challenge and predictor
variables using multivariable linear regression with repeat measurements while accounting for sow
identity as random effect.
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3.4. Piglets from Vaccinated Sows Showed Higher Titres of F4 Antibodies and SP-D in BALF
BALF samples were obtained at necropsy, two weeks after the challenge with the
virulent G. parasuis strains. Specific anti-F4 IgG were detected at higher levels in the BALF
from piglets born to vaccinated sows than from those born to nonvaccinated ones (two-
tailed Student t test, p = 0.0016; Figure 5). For the multivariable model, the ratio of specific
F4 IgG to the total IgGs in BALF was calculated and transformed into log10 in order to
achieve its normalization. The model showed a direct correlation of this ratio with sow
vaccination (p = 1.89 × 10−5; Table 5) and an additional association with the challenge
strain, with piglets challenged with P555/04 having a lesser level of F4 antibodies/total
IgG by −0.308 than those challenged with Nagasaki (Table 5).
Figure 5. Levels of IgG against F4 in bronchoalveolar lavage fluid (BALF). Piglets born to vaccinated
(VAC, pink and orange by biological sow) or nonvaccinated (NVAC, blue and green by biological
sow) sows were challenged with G. parasuis at 22 days of life and 2 weeks later were euthanized. At
that time, BALF samples were taken and F4 antibodies were measured by ELISA. The individual
value for each piglet and the average absorbance in the ELISA (horizontal lines) are shown in the
graph. Error bars are the standard deviation.
Table 5. Final model with the association of log10 of the ratio of specific F4 IgG to total IgG in
BALF and predictor variables using multivariable linear regression with repeat measurements while
accounting for sow identity as random effect. BALF samples were taken from piglets after necropsy.





Challenge strain Nagasaki Ref Ref 0.0165
P555/04 −0.308 (−0.564)–(−0.053)
SP-D detection in BALF obtained at necropsy two weeks after the challenge showed
that piglets from vaccinated sows had higher levels of this protein in BALF than those from
nonvaccinated sows (two-tailed Student t test, p = 0.0009; Figure 6). Multivariable statistical
model revealed that sow vaccination and challenge strain were significantly associated
with SP-D levels in BALF (Table 6). Piglets from vaccinated sows had higher SP-D levels in
BALF by 0.21 in comparison to piglets from nonvaccinated sows. P555/04 strain induced
lower levels of SP-D in BALF by −0.15 in comparison to the Nagasaki strain (Table 6).
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Figure 6. Levels of surfactant protein D (SP-D) in bronchoalveolar lavage fluid (BALF). Piglets born
to vaccinated (VAC, pink and orange by biological sow) or nonvaccinated (NVAC, blue and green
by biological sow) sows were challenged with G. parasuis at 22 days of life and 2 weeks later were
euthanized. At that time, BALF samples were taken and SP-D was measured by a capture ELISA.
The individual value for each piglet and the average absorbance in the ELISA (horizontal lines) are
shown in the graph. Error bars are the standard deviation.
Table 6. The final model with the association of SP-D level BALF in piglets and predictor
variables using multivariable linear regression with repeat measurements while accounting for
sow identity as random effect.





Challenge strain Nagasaki Ref Ref 0.0054
P555/04 −0.15 (−0.25)–(−0.046)
3.5. Sow Vaccination Did Not Inhibit Nasal Colonization of the Offspring by G. parasuis
To assess the colonization of the piglets by the challenge strains, nasal swabs were
analyzed using PCR. Using a virulence-specific PCR based on the leader sequence of vtaA
(LS-PCR), G. parasuis virulent strains were not detected in the nasal cavity of the piglets
before the challenge, but they were detected at the time of necropsy (Table 7). When we
used serovar specific PCRs to detect the challenge strains, serovar 5 was detected more
frequently in the nose of nonvaccinated animals (8/9) than in vaccinated ones (3/6), but this
difference was not statistically significant. In the piglets challenged with the P555/04 strain,
no differences were detected in the presence of serovar 13 in the nose of the vaccinated or
nonvaccinated piglets (Table 7). In addition, nonvirulent strains were detected at the time
of necropsy in most of the piglets in all the experimental groups.
Table 7. Detection of virulent (VIR) and nonvirulent (NVIR) Glaesserella parasuis strains in nasal swabs by LS-PCR and
serovar PCR at different times in piglets born to vaccinated or nonvaccinated sows after an intranasal challenge with two
virulent strains of G. parasuis (serovar SV5 Nagasaki and serovar SV13 P555/04) at 22 days of life.
D7 D39 D39
Challenge Strain Piglets from Sows VIR NVIR VIR NVIR SV 5/12 SV 13
Nagasaki Vaccinated 0/6 3/6 4/6 4/6 3/6
(50%) (67%) (67%) (50%)
Nonvaccinated 0/6
6/9 8/9 8/9 8/9
(67%) (89%) (89%) (88.9%)
P555/04 Vaccinated 0/5
2/5 4/5 4/5 4/5
(40%) (80%) (80%) (80%)
Nonvaccinated 0/8
4/8 4/8 7/8 4/8
(50%) (50%) (88%) (50%)
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4. Discussion
Maternal-derived immunity through the colostrum is essential for the protection of
young piglets, and sow vaccination is a way to increase maternal-derived antibody levels
in the piglets, which may help preventing infectious diseases in the postweaning period.
In our study, sow vaccination with the VtaA fragment F4 resulted in increased specific
antibody and high TGF-β levels in the sera of sows and their offspring. After the challenge
with virulent G. parasuis, piglets from vaccinated sows presented milder clinical signs and
increased SP-D and anti-F4 IgG antibody levels in their lungs. Besides these parameters,
piglets from vaccinated sows gained more weight after the infection than animals from
unvaccinated sows, reflecting a healthier status. These results confirm the importance of
maternal immunity in piglets, where sow vaccination may represent a good alternative in
contrast to piglet immunization for the control of early life diseases, since the immature
piglet immune system could benefit from their mother’s immunity transfer.
Sow sera and colostrum contained high anti-F4 IgG levels in response to the vaccine,
which were subsequently transferred to their offspring. It is reported that the transference
of maternal antibodies and other immune components can protect newborn piglets against
pathogens during lactation until their own immune system matures [21]. Together with
specific antibodies, an increase of TGF-β in piglets born to vaccinated sows was observed in
our study. These outcomes are in line with those reported in human [22], where an upregu-
lation of TGF-β in the mucosa of the upper airways was detected in neonates from mothers
vaccinated with Influenza pdm09 H1N1 adjuvanted vaccine during the pregnancy. Like-
wise, TGF-β levels were increased in vaccinated sow sera and especially more markedly
in colostrum. According to the literature, TGF-β represents one of the most important
cytokines transferred by lactation and helps in the maturation of the gastrointestinal tract
of the suckling animals helping in IgA class-switching [23–25]. A similar trend of maternal
transference, although much more diminished than that of TGF-β, was also observed in
our experiment with IL-10. These two cytokines have among its pleiotropic functions an
immune regulation activity and are principally secreted by T-regulatory cells. This immune
suppression in such young stage plays an important role in preventing the exacerbation of
the immune system, when the animals begin their contact with the environment and their
mucosae begin to be colonized [26,27]. Interestingly, an upregulated gene expression of
TGF-β was observed in the lungs of animals that were fully-resistant to Glässer’s disease
in comparison to susceptible ones [28]. In that study the authors relate this upregula-
tion with early tissue-repair and antibacterial activity. Moreover, an in vitro experiment
with PK-15 cells inoculated with virulent G. parasuis showed that TGF-β may also play
an important protective function by inducing the expression of fibronectin, collagen and
integrins necessary to preserve the integrity of the tissue and therefore prevent the invasion
of the pathogen [29]. Glässer’s disease is an inflammatory illness where TGF-β may help
in controlling an excessive inflammatory response to the infection, which may facilitate
bacterial clearance without the deleterious effects of an excessive activation that causes the
typical lesions of polyserositis of the disease. Induction of TGF-β was not observed in sows
vaccinated with vaccines against Mycoplasma hyopneumoniae or porcine circovirus type 2
(unpublished results). However, an increase in TGF-β was detected in piglets vaccinated
with F4 protein adjuvanted with Alum in comparison with its corresponding controls and
with other adjuvants like carbomer and complete Freund (unpublished results). For these
reasons, we consider that the mechanism by which TGF-β increases after vaccination with
F4 deserves further studies, as we cannot rule out a role of the adjuvant in the stimulation
or a direct induction by the F4 protein, as it has been observed with other bacterial adhesins
with anti-inflammatory activity [30].
To our knowledge, this is the first report showing that maternal vaccination signifi-
cantly increased the levels of SP-D in the piglets’ lungs. SP-D is a collectin, one of the first
humoral defenses against pathogens. SP-D is secreted by different epithelia throughout
the body, specially abundant in digestive and respiratory tracts, with functions comprising
from the opsonization and neutralization of pathogens to modulation of the immune re-
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sponse [31]. However, the link between sow vaccination and SP-D production in piglets’
lungs is not well understood and further research would be needed. In this study we
also found a correlation between sow vaccination and F4 antibodies in the BALF of the
offspring, which can play a role in bacterial opsonization to allow clearing by alveolar
macrophages [2].
Virulent G. parasuis strains colonize the upper respiratory tract before progressing
into the lung, where innate immunity mechanisms survive [2,32]. Our experiment showed
that both strains used for challenge were able to colonize the nasal cavity of the piglets
with different severity outcomes afterwards. Animals challenged with the Nagasaki strain
showed more inflammation in the nasal cavity (via inoculation) and a greater production
of SP-D and lung anti-F4 antibodies in comparison to P555/04, which we attribute to the
higher virulence of Nagasaki. Although we observed one fatal case of Glässer’s disease
in the nonvaccinated animal group challenged with the Nagasaki strain, we could not
fully evaluate the protection ability of the vaccine. Clinical signs were generally mild,
probably due to the use of sow-reared piglets [33]. On the other hand, nasal colonization
by virulent strains seemed to be reduced by vaccination, although not significantly, while
nonvirulent strains were found in most of the piglets included in the experiment. This
result may indicate that sow vaccination with F4, a protein fragment only found in virulent
G. parasuis strains, does not affect those commensal nonvirulent strains that colonize the
upper respiratory tract and are unable to reach the lung.
5. Conclusions
The vaccination of sows with VtaA fragment F4 had a clear impact on the levels
of specific antibodies, TGF-β and lung SP-D in their offspring. After the experimental
challenge using two different virulent strains of G. parasuis, piglets from vaccinated sows
suffered milder clinical signs and gained more weight than controls. These results indicate
that maternal vaccination could contribute to control Glässer’s disease in young piglets, a
strategy that deserves further research.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/vaccines9050534/s1, Figure S1: Levels of IgG against F4 in samples from individual piglets.
Piglets from two vaccinated sows (vaccinated with F4 at 4 and 2 weeks before farrowing; pink
and orange symbols and lines) and from two nonvaccinated sows were studied (blue and green
symbols and lines). Serum samples from the piglets were taken at 1, 2, 3 and 5 weeks of life and
tested for F4 antibodies by ELISA. At 22 days of life, piglets were challenged with G. parasuis. The
average absorbance in the ELISA of the piglets from each biological sow is shown in the graph (lines),
Figure S2. Levels of TGF-β in samples from individual piglets. Piglets from two vaccinated sows
(vaccinated with F4 at 4 and 2 weeks before farrowing; pink and orange symbols and lines) and
from two nonvaccinated sows were studied (blue and green symbols and lines). Serum samples
from the piglets were taken at 1, 2, 3 and 5 weeks of life and the level of TGF-β was determined. At
22 days of life, piglets were challenged with G. parasuis. The average quantity of TGF-β of the piglets
from each biological sow is shown in the graph (lines), Figure S3. Levels of IL-8 (A) and IL-10 (B)
in samples from individual piglets. Piglets from two vaccinated sows (vaccinated with F4 at 4 and
2 weeks before farrowing (pink and orange symbols and lines) and from two nonvaccinated sows
were studied (blue and green symbols and lines). Serum samples from the piglets were taken at 7, 15
and 21 days of life and the levels of IL-8 (A) and IL-10 (B) were determined. The average quantity of
IL-8 (A) and IL-10 (B) of the piglets from each biological sow is shown in the graph (lines), Table S1:
Primers used in the study for detection of Glaesserella parasuis.
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